Elicio Therapeutics, Inc. (ELTX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert T. Connelly | CEO, President & Director | 943.02k | -- | 1960 |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director | 48.12k | -- | 1947 |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer | 648.6k | -- | 1987 |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 721.09k | -- | 1966 |
| Dr. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | -- | -- | -- |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Strategy & Financial Officer and Treasurer | -- | -- | 1973 |
| Ms. Megan C. Filoon | General Counsel, Secretary & Compliance Officer | -- | -- | -- |
| Ms. Esther Welkowsky | Senior Vice President of Clinical Development | -- | -- | -- |
| Ms. Joy Seymour | VP & Head of Regulatory Affairs | -- | -- | -- |
| Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics | -- | -- | -- |
Elicio Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 32
Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
May 13, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
Elicio Therapeutics, Inc. Earnings Date